abstract |
The invention features an interferon-free therapy for the treatment of HCV. Preferably, treatment is for a shorter duration of treatment, such as 12 weeks or less. In one aspect, the treatment comprises administering at least two direct-acting antiviral agents to a subject with HCV infection, wherein the treatment lasts 12 weeks and does not include any administration of interferon or ribavirin; The at least two direct-acting antiviral agents include (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |